Organovo Shares Are Trading Higher After the Company Announced Phase 2 Results for FXR314. Study Results Demonstrated Statistically Significant Reduction in Liver Fat Content From Baseline in Patients Receiving FXR314 Compared to Placebo
Organovo公佈 FXR314 第二階段業績後,該公司股價走高。研究結果表明,與安慰劑相比,接受 FXR314 的患者的肝脂含量比基線顯著降低